Fulltext

Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective

Prasher P 1 , Sharma M 2 , Mehta M 3 , Paudel KR 4 , Satija S 5 , Chellappan DK 6 Show all authors , Dureja H 7 , Gupta G 8 , Tambuwala MM 9 , Negi P 10 , Wich PR 11 , Hansbro NG 12 , Hansbro PM 13 , Dua K 14

Affiliations 

  • 1 Department of Chemistry, University of Petroleum & Energy Studies, Dehradun, 248007, India
  • 2 Department of Chemistry, Uttaranchal University, Dehradun, 248007, India
  • 3 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia
  • 4 Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia
  • 5 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, Punjab, India
  • 6 Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
  • 7 Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, 124001, India
  • 8 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India
  • 9 School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, County Londonderry, BT52 1SA, Northern Ireland, United Kingdom
  • 10 School of Pharmaceutical Sciences, Shoolini University, Bajhol, Sultanpur, Solan, Himachal Pradesh, 173229, India
  • 11 Australian Centre for NanoMedicine, University of New South Wales, Sydney, NSW, 2052, Australia; School of Chemical Engineering, University of New South Wales, Sydney, NSW, 2052, Australia
  • 12 Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia
  • 13 Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia
  • 14 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Pharmaceutical Sciences, Shoolini University, Bajhol, Sultanpur, Solan, Himachal Pradesh, 173229, India; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia. Electronic address: Kamal.Dua@uts.edu.au
Chem Biol Interact, 2020 Jul 01;325:109125.
PMID: 32376238 DOI: 10.1016/j.cbi.2020.109125

Abstract

The apparent predicament of the representative chemotherapy for managing respiratory distress calls for an obligatory deliberation for identifying the pharmaceuticals that effectively counter the contemporary intricacies associated with target disease. Multiple, complex regulatory pathways manifest chronic pulmonary disorders, which require chemotherapeutics that produce composite inhibitory effect. The cost effective natural product based molecules hold a high fervor to meet the prospects posed by current respiratory-distress therapy by sparing the tedious drug design and development archetypes, present a robust standing for the possible replacement of the fading practice of poly-pharmacology, and ensure the subversion of a potential disease relapse. This study summarizes the experimental evidences on natural products moieties and their components that illustrates therapeutic efficacy on respiratory disorders.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications